According to a new study presented at the American College of Radiology (ACR) annual meeting, the use of follow-up imaging is significantly less when initial emergency department (ED) ultrasound examinations are interpreted by a radiologist than a nonradiologist. The work, conducted by researchers at the Harvey L. Neiman Health Policy Institute, was named an ACR 2017 Gold Merit Abstract Award recipient in the Advocacy, Economics and Health Policy category.

Intelerad Medical Systems launched CosmosOne, a living medical archive that centralizes all types of patient health information, so it can be accessed and shared in real-time, regardless of its source or format.

May 26, 2017 — Double Black Imaging announced that it has acquired the Image Systems PACS (picture archiving and communication system) Display Business from Richardson Electronics Ltd.

NucleusHealth has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Nucleus.io technology.

At the 2017 annual meeting of the Society for Imaging Informatics in Medicine (SIIM), June 1-3 in Pittsburgh, Konica Minolta Healthcare Americas Inc. will showcase advanced specialty viewing capabilities of the Exa Enterprise Imaging platform. The platform facilitates the viewing of large medical imaging files, such as 3-D mammography, cardiac imaging and nuclear medicine, quickly and efficiently on existing workstations throughout the enterprise. With the Exa diagnostic quality Zero Footprint Universal Viewer, clinicians can view these images and more from any modality and any vendor. Exa delivers relevant priors from the picture archiving and communication system (PACS) or vendor neutral archive (VNA), including 3-D breast tomosynthesis and cardiovascular images quickly and securely.

May 25, 2017 —The Royal College of Radiologists (RCR) has published a new edition of its guidance on the application and best practice of interventional oncology.

Interventional oncology is a fast-moving discipline that directly overlays the RCR’s two specialties of radiology and oncology; it concerns both the diagnosis and interventional treatment of cancer using image guidance techniques. The college’s original guidance, released in 2012, has been revisited to ensure clinicians remain up-to-date.

FDA says gadolinium retention in the brain is not a safety issue

A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for magnetic resonance imaging (MRI) has not identified adverse health affects from gadolinium retained in the brain. The FDA released a drug safety communication regarding all gadolinium-based contrast agents (GBCAs) earlier this week. 

A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a small peptide that binds to a protein found in high-risk prostate cancers. By linking the peptide to a clinically used magnetic resonance imaging (MRI) contrast agent, the group used MRI to identify aggressive, metastatic tumors in mouse models of prostate cancer. The system is a promising step for reliable early detection and treatment of high-risk, life-threatening prostate cancer.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now